Patients with myelofibrosis need to be younger than 60 years old for bone marrow transplantation, which should be analyzed according to the patient’s condition.
Patients in the low-risk group are mainly treated with supportive therapy, and the intermediate-risk group is divided into intermediate-risk group 1 and 2. Intermediate-risk group 1 should decide whether to perform stem cell transplantation based on anemia, symptom scores, and poor prognosis of genetic mutations, etc. Intermediate-risk group 2 and high-risk can be performed with allogeneic hematopoietic stem cell bone marrow transplantation, and age should be less than 60 years old, and risks should be weighed when performing bone marrow transplantation.
When the patient’s age is higher than 60 years old, the efficacy of hematopoietic stem cell transplantation can be limited by factors such as poor function of the underlying organs, and the risk of complications such as infection and organ failure can be increased, so it is not recommended.
To summarize, a professional assessment should be made by a doctor in a regular hospital. If the patient’s own condition meets the criteria for bone marrow transplantation and the bone marrow match is successful, the transplantation can be carried out.